Hansoh Pharmaceutical's (HKG:3692) attributable profit rose 33% to 4.37 billion yuan in 2024 from 3.28 billion yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Earnings per share increased to 0.73 yuan from 0.52 yuan in the previous year.
Revenue grew 21% to 12.3 billion yuan from 10.1 billion yuan a year earlier.
The company declared a final dividend of HK$0.1353 per share, payable July 25 to shareholders on record as of July 9.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.